• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by RenovoRx Inc.

    8/14/25 4:42:08 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNXT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    RenovoRx, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    75989R107

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    75989R107


    1Names of Reporting Persons

    AWM Investment Company, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,870,225.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,870,225.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,870,225.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  AWM Investment Company, Inc., a Delaware Corporation (AWM), is the investment adviser to Special Situations Cayman Fund, L.P. (CAYMAN), Special Situations Fund III QP, L.P. (SSFQP) and Special Situations Life Sciences Fund, L.P. (SSLS). (CAYMAN, SSFQP, and SSLS will hereafter be referred to as the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 1,064,431 shares of Common Stock of the Issuer (the Shares) held by SSFQP, 296,698 shares of Common Stock held by CAYMAN and 509,096 shares of Common Stock held by SSLS


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    RenovoRx, Inc.
    (b)Address of issuer's principal executive offices:

    2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, CALIFORNIA, 94040
    Item 2. 
    (a)Name of person filing:

    The person filing this report is AWM Investment Company, Inc., a Delaware corporation (AWM), which is the investment adviser to Special Situations Cayman Fund, L.P., a Cayman Islands Limited Partnership (CAYMAN), Special Situations Fund III QP, L.P., a Delaware limited partnership (SSFQP) and Special Situations Life Sciences Fund, L.P., a Delaware limited partnership (SSLS), (CAYMAN, SSFQP, SSPE and SSLS, will hereafter be referred to as the Funds). The principal business of each Fund is to invest in equity and equity-related securities and other securities of any kind or nature. David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are members of: SSCayman, L.L.C., a Delaware limited liability company (SSCAY), the general partner of CAYMAN; MGP Advisers Limited Partnership, a Delaware limited partnership (MGP), the general partner of SSFQP and LS Advisers, L.L.C., a New York limited liability company (LS). Greenhouse and Stettner are also controlling principals of AWM.
    (b)Address or principal business office or, if none, residence:

    The principal business address for AWM is c/o Special Situations Funds, 527 Madison Avenue, Suite 2600, New York, NY 10022.
    (c)Citizenship:

    AWM is a Delaware Corporation.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    75989R107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,870,225
    (b)Percent of class:

    5.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    AWM is the investment adviser to each of the Funds. As the investment adviser to the Funds, AWM holds sole voting power over 1,064,,431 shares of Common Stock of the Issuer (the Shares) held by SSFQP, 296,698 shares of Common Stock held by CAYMAN and 509,096 shares of Common Stock held by SSLS. Greenhouse and Stettner are members of: SSCAY, the general partner of CAYMAN; MGP, the general partner of SSFQP; MG, the general partner of SSPE; and LS, the general partner of SSLS. Greenhouse and Stettner are also controlling principals of AWM.

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    AWM is the investment adviser to each of the Funds. As the investment adviser to the Funds, AWM holds sole investment power over 1,064,,431 shares of Common Stock of the Issuer (the Shares) held by SSFQP, 296,698 shares of Common Stock held by CAYMAN and 509,096 shares of Common Stock held by SSLS. Greenhouse and Stettner are members of: SSCAY, the general partner of CAYMAN; MGP, the general partner of SSFQP; MG, the general partner of SSPE; and LS, the general partner of SSLS. Greenhouse and Stettner are also controlling principals of AWM.

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    AWM Investment Company, Inc.
     
    Signature:Adam Stettner
    Name/Title:Executive Vice President
    Date:06/30/2025
    Get the next $RNXT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNXT

    DatePrice TargetRatingAnalyst
    11/1/2021$16.00Buy
    Roth Capital
    10/6/2021$15.00Buy
    Maxim Group
    More analyst ratings

    $RNXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Bagai Shaun

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    7/3/25 4:45:33 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Agah Ramtin

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    7/3/25 4:45:34 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Clinical Officer Gentry Leesa

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    7/3/25 4:45:31 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Agah Ramtin bought $29,400 worth of shares (21,000 units at $1.40), increasing direct ownership by 3% to 734,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    6/9/25 6:03:27 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $13,500 worth of shares (15,000 units at $0.90), increasing direct ownership by 1% to 1,113,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/17/25 6:10:32 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Bagai Shaun bought $6,821 worth of shares (7,500 units at $0.91), increasing direct ownership by 2% to 320,040 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/16/25 6:08:22 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

    Revenue from RenovoCath® device totaled over $400,000 for the Second Quarter 2025 As of June 30, 2025, the Company had $12.3 million in cash and cash equivalents Management to host conference call today at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced its financial results and business update to shareholders for the second quarter ended June 30, 2025. "We are pleased to report second quarter 2025 revenue of over $400,000. This growth highlights the strong clinical need and market demand for our

    8/14/25 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

    RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are currently purchasing and have made repeat orders of RenovoCath for interventional radiology procedures RenovoRx hires Senior Director of Sales and Market Development to coordinate, execute, and expand commercialization strategy MOUNTAIN VIEW, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery devic

    8/6/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

    Several Esteemed Cancer Centers to Commence Patient Enrollment Before the End of September The Registry Study, Known as PanTheR, will Expand the Safety and Performance Data of the FDA-Cleared RenovoCath® Device, and its Associated Survival Outcomes in Patients Diagnosed with Solid Tumors Cancer Centers in the Registry Study will Purchase RenovoCath Devices from RenovoRx RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, today announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461). The initiation of t

    7/28/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on RenovoRx with a new price target

    Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

    11/1/21 11:49:10 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on RenovoRx with a new price target

    Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

    10/6/21 8:24:28 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    SEC Filings

    View All

    SEC Form 8-K filed by RenovoRx Inc.

    8-K - RenovoRx, Inc. (0001574094) (Filer)

    8/14/25 5:00:57 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by RenovoRx Inc.

    SCHEDULE 13G/A - RenovoRx, Inc. (0001574094) (Subject)

    8/14/25 4:42:08 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by RenovoRx Inc.

    10-Q - RenovoRx, Inc. (0001574094) (Filer)

    8/14/25 4:08:03 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Leadership Updates

    Live Leadership Updates

    View All

    RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

    LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

    6/10/24 8:30:00 AM ET
    $IMMX
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Closes $6.1 Million Private Placement

    With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c

    1/29/24 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

    RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre

    11/16/23 8:35:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Financials

    Live finance-specific insights

    View All

    RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

    Revenue from RenovoCath® device totaled over $400,000 for the Second Quarter 2025 As of June 30, 2025, the Company had $12.3 million in cash and cash equivalents Management to host conference call today at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced its financial results and business update to shareholders for the second quarter ended June 30, 2025. "We are pleased to report second quarter 2025 revenue of over $400,000. This growth highlights the strong clinical need and market demand for our

    8/14/25 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

    RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced it will host its second quarter 2025 financial results and business highlights conference call on August 14, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. On the call, RenovoRx management is expected to discuss the latest developments and achievements for the Company's ongoing RenovoCath device commercialization efforts and for the Company's pivotal Phase III TIGeR-P

    7/14/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

    Q1 2025 RenovoCath® Revenues of ~$200,000, Exceeding Expectations and Anticipated to Continue Growing Sequentially with New Customer Purchase Orders and Reorders Cash on Hand of $14.6 Million Anticipated to Fully Fund both RenovoCath Commercialization Scale-up and Continued Progress Towards the Completion of the Ongoing Phase III TIGeR-PaC Clinical Trial Completion of the TIGeR-PaC Clinical Trial Enrollment and Review of Second Interim Analysis by Data Monitoring Committee on Target for 2025 Company to Host Conference Call at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializ

    5/15/25 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

    SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

    2/14/23 4:51:34 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by RenovoRx Inc.

    SC 13G - RenovoRx, Inc. (0001574094) (Subject)

    4/14/22 2:24:24 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by RenovoRx Inc.

    SC 13G - RenovoRx, Inc. (0001574094) (Subject)

    2/14/22 6:33:04 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care